Test Price
800 AED✅ Home Collection Available
TEL/AML1 (ETV6-RUNX1) Fusion Quantitative PCR Test | Dubai, UAE | 800 AED
Executive Summary & Core Metrics
Clinical Excellence Guarantee
- 99.9% Diagnostic Sensitivity via ISO Accredited Real-Time qPCR & WGS.
- Methodology: Real-Time PCR (qPCR) and Whole Genome Sequencing (WGS) for MRD monitoring.
Premium Patient Logistics
- Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Post-Test Clinical Guidance: Complimentary telephonic interpretation by a clinical expert.
Insurance & Compliance
Direct Billing Verification: Check your coverage instantly via WhatsApp +971 54 548 8731. Test requires a Doctor's prescription; not applicable for surgery, pregnancy, or travel clearance. Fully compliant with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The TEL/AML1 fusion transcript, resulting from t(12;21)(p13;q22), is the most frequent genetic abnormality in childhood B-cell precursor acute lymphoblastic leukemia (ALL). Early and precise quantification is a cornerstone of risk stratification and minimal residual disease (MRD) monitoring. This quantitative PCR assay provides the molecular precision necessary for treatment response evaluation.
| Feature | Our Test (TEL/AML1 qPCR) | Closest Alternative (FISH) |
|---|---|---|
| Analytical Precision | Sensitivity down to 1 in 10⁰ cells (0.01%) | Sensitivity limit ~1-5% |
| Methodology | Real-Time PCR (qPCR) & WGS | Fluorescence In Situ Hybridization |
| Turnaround Time | 3-4 Business Days | 7-10 Days |
| MRD Monitoring Utility | Gold Standard for dynamic monitoring | Limited to baseline diagnosis |
*Specimen: Bone Marrow Aspirate or Peripheral Blood – Hospital Extraction Only. Transport immediately in validated cold-chain to preserve RNA integrity.
Physician Insight & Safety Protocols
"A positive TEL/AML1 fusion result in pediatric B-cell precursor ALL is associated with a favorable prognosis, yet accurate quantification through qPCR is essential for MRD-directed therapy. I counsel families that each log reduction reflects a measurable treatment response, and our role is to translate these molecular data into clear, actionable guidance for the managing oncologist."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Critical Medication Advisory
⚠ Critical Medication Warning
Do not discontinue or modify any prescribed chemotherapy, corticosteroid, or supportive medication without explicit consultation with your treating oncologist. Alterations in medication status can affect MRD levels and clinical stability.
Exclusion Criteria & ER Red Flags
- Specimen clotted, hemolyzed, or volume insufficient for RNA extraction.
- Collection tube not immediately placed in cold-chain or delay exceeds 2 hours.
- Patient on active antibiotic therapy for unrelated infection; reschedule if possible.
- Seek immediate emergency care if the patient develops fever > 38.3°C, unexplained bleeding, or severe respiratory distress.
Patient FAQ & Clinical Guidance
1. What is the clinical significance of TEL/AML1 fusion quantification in pediatric ALL?
Quantitative PCR detects one leukemic cell among 10,000 normal cells, providing a molecular-level measure of residual disease that standard morphology cannot identify. This allows clinicians to stratify risk accurately and adjust therapy intensity based on the patient's molecular response.
2. How does a 4-log reduction in MRD correlate with long-term prognosis?
A 4-log reduction from baseline after induction therapy signifies an excellent early molecular response. Patients achieving this threshold are classified in the low-risk MRD category, which generally predicts favorable long-term outcomes and may allow for de-escalation of therapy under the guidance of the treating oncologist.
3. What are the mandatory requirements for bone marrow specimen collection?
A doctor's prescription is mandatory. The bone marrow aspirate must be collected by a qualified medical professional within an accredited hospital setting. Specimens are transported immediately in a validated cold-chain kit to preserve RNA integrity for accurate quantitative analysis.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This test is performed under the regulatory oversight of the Dubai Health Authority (DHA) and adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling. Health information security complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | TEL/AML1 (ETV6-RUNX1) Fusion Quantitative PCR |
| Price (AED) | 800 |
| Turnaround Time | 3-4 Business Days |
| Sample Type / Matrix | Bone Marrow Aspirate or Peripheral Blood – Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Real-Time Quantitative PCR (qPCR) & Whole Genome Sequencing (WGS) |
| ICD-10-CM Code | C91.0 |
| LOINC Code | 76518-9 |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians